References
1. Kobelska-Dubiel N, Klincewicz B, Cichy W. Liver disease in cystic
fibrosis. Prz Gastroenterol 2014;9(3):136–141.
2. Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis And Liver Disease.
StatPearls Publishing; 2020.
3. Paranjape SM, Mogayzel PJ. Cystic fibrosis in the era of precision
medicine. Paediatr Respir Rev 2018;25:64–72.
4. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M,
Cohen M, Armoni S, Yaakov Y, Pugatch T, et al. Chronic ataluren (PTC124)
treatment of nonsense mutation cystic fibrosis. Eur Respir J
2011;38(1):59–69.
5. Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of
Cystic Fibrosis. Clin Liver Dis 2019;23(2):263–277.
6. Minagawa N, Nagata J, Shibao K, Masyuk AI, Gomes DA, Rodrigues MA,
Lesage G, Akiba Y, Kaunitz JD, Ehrlich BE, et al. Cyclic AMP Regulates
Bicarbonate Secretion in Cholangiocytes Through Release of ATP Into
Bile. Gastroenterology 2007;133(5):1592–1602.
7. Siano M, De Gregorio F, Boggia B, Sepe A, Ferri P, Buonpensiero P, Di
Pasqua A, Raia V. Ursodeoxycholic acid treatment in patients with cystic
fibrosis at risk for liver disease. Dig Liver Dis 2010;42(6):428–431.
8. Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis
related liver disease-another black box in hepatology. Int J Mol Sci
2014;15(8):13529–13549.
9. Stollar F, Adde FV, Cunha MT, Leone C, Rodrigues JC.
Shwachman-Kulczycki score still useful to monitor cystic fibrosis
severity. Clinics 2011;66(6):979–983.
10. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and
projected estimates of survival for people with cystic fibrosis using
baseline characteristics: A longitudinal study using UK patient registry
data. J Cyst Fibros 2018;17(2):218–227.
11. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D,
Padoan R, Giunta A. Liver disease in cystic fibrosis: A prospective
study on incidence, risk factors, and outcome. Hepatology
2002;36(6):1374–1382.
12. Al-Mahroos F. Cystic fibrosis in Bahrain incidence, phenotype, and
outcome. J Trop Pediatr 1998;44(1):35–39.
13. Rawashdeh M, Manal H. Cystic fibrosis in Arabs: A prototype from
Jordan. Ann Trop Paediatr 2000;20(4):283–285.
14. Naguib ML, Schrijver I, Gardner P, Pique LM, Doss SS, Abu Zekry MA,
Aziz M, Nasr SZ. Cystic fibrosis detection in high-risk Egyptian
children and CFTR mutation analysis. J Cyst Fibros 2007;6(2):111–116.
15. Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR,
Ling SC. Features of Severe Liver Disease With Portal Hypertension in
Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol
2016;14(8):1207-1215.e3.
16. Sharma DG. Cystic Fibrosis Treatment & Management: Approach
Considerations, Diet and Exercise, Surgical Management of Complications.
Medscape Med News 2022.
17. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H. Cystic Fibrosis
Liver Disease: Outcomes and Risk Factors in a Large Cohort of French
Patients. Hepatology 2019;69(4):1648–1656.
18. Fagundes EDT, Roquete ML V., Penna FJ, Reis FJC, Goulart EMA, Duque
CG. Fatores de risco da hepatopatia da fibrose cística. J Pediatr (Rio
J) 2005;81(6):478–484.
19. Efrati O, Barak A, Modan-Moses D, Augarten A, Vilozni D, Katznelson
D, Szeinberg A, Yahav J, Bujanover Y. Liver cirrhosis and portal
hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol
2003;15(10).
20. Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease
in children. World J Hepatol 2021;13(11):1727–1742.
21. Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver
Disease: A Channelopathy Leading to Alterations in Innate Immunity and
in Microbiota. Cmgh 2019;8(2):197–207.
22. Diwakar V, Pearson L, Beath S. Liver disease in children with cystic
fibrosis. Paediatr Respir Rev 2001;2(4):340–349.
23. Williams SM, Goodman R, Thomson A, Mchugh K, Lindsell DRM.
Ultrasound evaluation of liver disease in cystic fibrosis as part of an
annual assessment clinic: A 9-year review. Clin Radiol
2002;57(5):365–370.
24. Bock JM, Schien M, Fischer C, Naehrlich L, Kaeding M,
Guntinas-Lichius O, Gerber A, Arnold C, Mainz JG. Importance to question
sinonasal symptoms and to perform rhinoscopy and rhinomanometry in
cystic fibrosis patients. Pediatr Pulmonol 2017;52(2):167–174.
25. Nährlich L, Burkhart M, Wiese Helfen Forschen Heilen B. Deutsches
Mukoviszidose. 2015.
26. Minicucci L, Lorini R, Giannattasio A, Colombo C, Iapichino L, Reali
MF, Padoan R, Calevo MG, Casciaro R, De Alessandri A, et al. Liver
disease as risk factor for cystic fibrosis-related diabetes development.
Acta Paediatr Int J Paediatr 2007;96(5):736–739.
27. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C,
Cutting GR, Durie PR, LeGrys VA, Massie J, Parad RB, et al. Guidelines
for Diagnosis of Cystic Fibrosis in Newborns through Older Adults:
Cystic Fibrosis Foundation Consensus Report. J Pediatr
2008;153(2):S4–S14.
28. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B,
Castaldo G, Castellani C, Cipolli M, Colombo C, et al. Genetic modifiers
of liver disease in cystic fibrosis. Jama 2009;302(10):1076–1083.
29. Slieker MG, Deckers-Kocken JM, Uiterwaal CSPM, Van Der Ent CK,
Houwen RHJ, Colombo C, Battezzati PM, Crosignani A. Risk factors for the
development of cystic fibrosis related liver disease [2] (multiple
letters). Hepatology 2003;38(3):775–776.
30. Rowland M, Bourke B. Liver disease in cystic fibrosis. Curr Opin
Pulm Med 2011;17(6):461–466.
31. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic
fibrosis-related liver disease. Cochrane Database Syst Rev 2017;2017(9).
32. Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G,
Ling SC, Narkewicz MR, Leung DH. A Multidisciplinary Approach to
Pretransplant and Posttransplant Management of Cystic
Fibrosis–Associated Liver Disease. Liver Transplant
2019;25(4):640–657.